Helen M. Boudreau
Helen M. Boudreau has served as a member of the board of directors of Premier since June 2020. She previously served as Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute and held Chief Financial Officer roles at public and private biotech companies.
Over the course of her more than 30-year career, Boudreau held positions of increasing scope and responsibility in finance in the pharmaceutical industry, including roles as Chief Financial Officer for Novartis Corporation in the U.S., global Chief Financial Officer for Novartis Oncology and senior finance positions at Pfizer Inc. Her experience spans multiple industries and functions, and includes roles at Bank of America, McKinsey & Company, PepsiCo, Pfizer and Novartis.
Boudreau currently serves on the board of directors and as chair of the Audit Committee and member of the Compensation Committee of each of Shattuck Labs Inc., a NASDAQ-listed company, and Field Trip Health Ltd., a company listed on the Canadian Securities Exchange. She also serves on the board of directors and as chair of the Audit Committee of Evaxion Biotech, a NASDAQ-listed company, and on the board of directors of a private biotech. She previously served as a board member and Audit Committee chair for NASDAQ-listed Proteostasis Therapeutics Inc.
Boudreau received a bachelor’s degree from the University of Maryland and an MBA from the Darden School at the University of Virginia.